Oligodendroglioma historical perspective: Difference between revisions
Jump to navigation
Jump to search
Sara Mohsin (talk | contribs) |
Sara Mohsin (talk | contribs) |
||
| (19 intermediate revisions by the same user not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
In 1926, the term "[[oligodendroglioma]]" was first coined by Bailey and Cushing, and was first described and published by W. E. Carnegie Dickson. [[Oligodendrogliomas]] were first [[Classification|classified]] and [[Grading (tumors)|graded]] in a [[system]] devised by Bailey and Cushing, and later revised by Kernohan, Ringertz, and others, and since then, [[classification]] and [[Grading (tumors)|grading]] of [[gliomas]] have [[evolved]] over the time. Modern [[World Health Organization|WHO]] [[classification]] of [[oligodendrogliomas]] was first published in 1979 and revised four times since then, with the most recent published in 2016. In 1997, a Westergaard's [[Study design|study]] showed that [[patients]] younger than 20 [[Year|years]] had a [[median]] [[Survival rate|survival]] of 17.5 years. In 2001, a [[Study design|study]] at [[Mayo Clinic]] was conducted to [[Assessment and Plan|assess]] the [[prognostic]] [[Value (mathematics)|value]] of [[histological]] [[Grading (tumors)|grading]] of [[Oligodendroglial tumor|oligodendroglial tumors]] in [[Grading (tumors)|tumor grading]] and [[Significant figure|significant]] [[Association (statistics)|association]] with [[Survival analysis|survival]] was found for [[age]], high [[Cellular|cellularity]], presence of [[mitoses]], [[endothelial]] [[hypertrophy]] and [[proliferation]] and [[necrosis]] on [[univariate]][[analysis]], but only [[age]] and presence of [[endothelial]] [[proliferation]] were found to be [[Independent assortment|independently]] [[Association (statistics)|associated]] with [[Survival rate|survival]] on a multivariable [[analysis]]. In 2009, ''[[Mutation|NJDS]]''[[mutation]] was first identified in the [[pathogenesis]] of [[oligodendroglioma]] by Kevin Smith. It was suggested in 2009 ASCO Annual Meeting that [[PCV regimen|PCV]] [[therapy]] may be [[superior]] in [[efficacy]] to the [[New|newer]] [[temozolomide]] [[therapy]]. [[Radiation|Irradiation]] of [[pituitary adenoma]] was also [[Discovery system|discovered]] to be [[Association (statistics)|associated]] with [[oligodendroglioma]] by Kevin Smith et al. | |||
==Historical Perspective== | ==Historical Perspective== | ||
*The term | *The [[Term logic|term]] [[oligodendroglioma]] was [[derived]] from the [[Greek key|Greek]] words "''[[oligo]]''" [[Mean|meaning]] [[Fewmets|few]] and "''[[Dendrons|dendro]]''" [[Mean|meaning]] [[Treeshrew|trees]]. | ||
*In 1926, the term "oligodendroglioma" was first coined by Bailey and Cushing following the observation that the [[tumor]] cells are morphologically similar to [[oligodendrocyte]]s<ref name="pmid19322536">{{cite journal| author=Hartmann C, von Deimling A| title=Molecular pathology of oligodendroglial tumors. | journal=Recent Results Cancer Res | year= 2009 | volume= 171 | issue= | pages= 25-49 | pmid=19322536 | doi=10.1007/978-3-540-31206-2_2 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19322536 }} </ref> | *In 1926, the term "[[oligodendroglioma]]" was first coined by Bailey and Cushing following the [[observation]] that the [[tumor]] [[Cells (biology)|cells]] are [[Morphological computation|morphologically]] similar to [[oligodendrocyte]]s.<ref name="pmid19322536">{{cite journal| author=Hartmann C, von Deimling A| title=Molecular pathology of oligodendroglial tumors. | journal=Recent Results Cancer Res | year= 2009 | volume= 171 | issue= | pages= 25-49 | pmid=19322536 | doi=10.1007/978-3-540-31206-2_2 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19322536 }} </ref> | ||
*In 1926, oligodendroglioma was first described and published by W. E. Carnegie Dickson<ref name="drmet">{{Citation |last=Dickson |first=WEC|year=1926 |title=Proceeding of the Section of Neurology of the Royal Society Medicine: Oligodendroglioma of Floor of Third Ventricle |publisher=Brain-A journal of neurology |publication-place= |page=578 |url=http://brain.oxfordjournals.org/content/49/4/578 |accessdate= 11/20/2015}}</ref> | *In 1926, [[oligodendroglioma]] was first described and published by W. E. Carnegie Dickson.<ref name="drmet">{{Citation |last=Dickson |first=WEC|year=1926 |title=Proceeding of the Section of Neurology of the Royal Society Medicine: Oligodendroglioma of Floor of Third Ventricle |publisher=Brain-A journal of neurology |publication-place= |page=578 |url=http://brain.oxfordjournals.org/content/49/4/578 |accessdate= 11/20/2015}}</ref> | ||
*In 1926, oligodendrogliomas were first classified and graded in a system devised by Bailey and Cushing, and later revised by Kernohan, Ringertz, and others, and since then, classification and grading of gliomas have evolved over the time | *In 1926, [[oligodendrogliomas]] were first [[Classification|classified]] and [[Grading (tumors)|graded]] in a [[system]] devised by Bailey and Cushing, and later revised by Kernohan, Ringertz, and others, and since then, [[classification]] and [[Grading (tumors)|grading]] of [[gliomas]] have [[evolved]] over the [[Time series|time]]. | ||
*In 1979, modern classification of gliomas based on the World Health Organization (WHO) Classification of Central Nervous System Tumors was first published and revised four times since then | *In 1979, modern [[classification]] of [[gliomas]] [[Base|based]] on the [[World Health Organization]] ([[WHO]]) [[Classification]] of [[Central nervous system|Central Nervous System]] [[Tumors]] was first published and revised four times since then. | ||
*In 1997, a Westergaard's study showed that patients younger than 20 years had a median survival of 17.5 years<ref name="EngelhardStelea2003">{{cite journal|last1=Engelhard|first1=Herbert H|last2=Stelea|first2=Ana|last3=Mundt|first3=Arno|title=Oligodendroglioma and anaplastic oligodendroglioma:|journal=Surgical Neurology|volume=60|issue=5|year=2003|pages=443–456|issn=00903019|doi=10.1016/S0090-3019(03)00167-8}}</ref> | *In 1997, a Westergaard's [[Study design|study]] showed that [[patients]] younger than 20 [[Year|years]] had a [[median]] [[Survival analysis|survival]] of 17.5 [[Year|years]].<ref name="EngelhardStelea2003">{{cite journal|last1=Engelhard|first1=Herbert H|last2=Stelea|first2=Ana|last3=Mundt|first3=Arno|title=Oligodendroglioma and anaplastic oligodendroglioma:|journal=Surgical Neurology|volume=60|issue=5|year=2003|pages=443–456|issn=00903019|doi=10.1016/S0090-3019(03)00167-8}}</ref> | ||
*In 2009 Oxford Neurosymposium study by Kevin Smith, it was first discovered that there is a 69% correlation between NJDS gene mutation and oligodendroglial tumor initiation<ref name="history">Etiology of oligodendroglioma. Wikipedia. https://en.wikipedia.org/wiki/Oligodendroglioma</ref> | *In March 2001, 7 [[Neuropathologist|neuropathologists]] and 6 [[Surgery|surgical]] [[pathologists]] experienced in [[Brain tumor|brain tumor-]][[diagnosis]] [[Assessment and Plan|assessed]] 124 [[Oligodendroglial tumor|oligodendroglial tumors]] operated at the [[Mayo Clinic]] during the [[period]] of 1960 to 1990. In this [[Study design|study]], the [[prognostic]] [[Value (mathematics)|value]] of [[Histological grade|histological grading]] of [[Oligodendroglial tumor|oligodendroglial tumors]] in [[tumor]] [[Grading (tumors)|grading]] was [[Assessment and Plan|assessed]], and [[Significant figure|significant]] [[Association (statistics)|association]] with [[Survival analysis|survival]] was found for [[age]], high [[Cellular|cellularity]], presence of [[mitoses]], [[endothelial]] [[hypertrophy]] and [[proliferation]] and [[necrosis]] on [[univariate]] [[analysis]]. However, only [[age]] and presence of [[endothelial]] [[proliferation]] were found to be independently [[Association (statistics)|associated]] with [[Survival analysis|survival]] on a [[Multivariable calculus|multivariable]] [[analysis]].<ref name="pmid11245209">{{cite journal| author=Giannini C, Scheithauer BW, Weaver AL, Burger PC, Kros JM, Mork S et al.| title=Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. | journal=J Neuropathol Exp Neurol | year= 2001 | volume= 60 | issue= 3 | pages= 248-62 | pmid=11245209 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11245209 }} </ref> | ||
*2009 ASCO Annual Meeting, | *In 2009 [[Oxford Forum|Oxford]] Neurosymposium study by Kevin Smith, it was first [[Discovery system|discovered]] that there is a 69% [[correlation]] between NJDS [[gene mutation]] and [[oligodendroglial tumor]] [[Initiation (chemistry)|initiation]].<ref name="history">Etiology of oligodendroglioma. Wikipedia. https://en.wikipedia.org/wiki/Oligodendroglioma</ref> | ||
*[[radiation| | *In 2009 ASCO Annual Meeting, it was [[Suggestion|suggested]] that [[PCV regimen|PCV]] [[therapy]] may be [[superior]] in [[efficacy]] to the [[New|newer]] [[temozolomide]] [[therapy]]. This [[Study design|study]] showed that [[median]] [[Time-series|time]] to progression for [[patients]] with 1p19q co-deletion is longer following [[PCV regimen|PCV]] alone (7.6 [[Year|years]]) than with [[temozolomide]] alone (3.3 [[Year|years]]); [[median]] overall [[Survival analysis|survival]] is also longer with [[PCV regimen|PCV]] [[Treatments|treatment]] versus [[temozolomide]] [[Treatments|treatment]] (not reached, vs. 7.1 [[Year|years]]).<ref>{{cite journal|doi=10.1200/jco.2009.27.15s.2014}}</ref> | ||
* | *Kevin Smith et al also [[Discovery system|discovered]] that [[radiation|irradiation]] of [[pituitary adenoma]] is [[Association (statistics)|associated]] with [[Precipitation (chemistry)|precipitation]] of [[oligodendroglioma]]. | ||
*In 2016 edition of the most recent [[World Health Organization|WHO]] [[classification]], [[gliomas]] are [[Classification|classified]] based not only on [[histopathologic]] [[appearance]] but also on well-established [[molecular]] [[Parameter|parameters]]. | |||
==References== | ==References== | ||
Latest revision as of 14:01, 13 August 2019
|
Oligodendroglioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Oligodendroglioma historical perspective On the Web |
|
American Roentgen Ray Society Images of Oligodendroglioma historical perspective |
|
Risk calculators and risk factors for Oligodendroglioma historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]Sujit Routray, M.D. [3]
Overview
In 1926, the term "oligodendroglioma" was first coined by Bailey and Cushing, and was first described and published by W. E. Carnegie Dickson. Oligodendrogliomas were first classified and graded in a system devised by Bailey and Cushing, and later revised by Kernohan, Ringertz, and others, and since then, classification and grading of gliomas have evolved over the time. Modern WHO classification of oligodendrogliomas was first published in 1979 and revised four times since then, with the most recent published in 2016. In 1997, a Westergaard's study showed that patients younger than 20 years had a median survival of 17.5 years. In 2001, a study at Mayo Clinic was conducted to assess the prognostic value of histological grading of oligodendroglial tumors in tumor grading and significant association with survival was found for age, high cellularity, presence of mitoses, endothelial hypertrophy and proliferation and necrosis on univariateanalysis, but only age and presence of endothelial proliferation were found to be independently associated with survival on a multivariable analysis. In 2009, NJDSmutation was first identified in the pathogenesis of oligodendroglioma by Kevin Smith. It was suggested in 2009 ASCO Annual Meeting that PCV therapy may be superior in efficacy to the newer temozolomide therapy. Irradiation of pituitary adenoma was also discovered to be associated with oligodendroglioma by Kevin Smith et al.
Historical Perspective
- The term oligodendroglioma was derived from the Greek words "oligo" meaning few and "dendro" meaning trees.
- In 1926, the term "oligodendroglioma" was first coined by Bailey and Cushing following the observation that the tumor cells are morphologically similar to oligodendrocytes.[1]
- In 1926, oligodendroglioma was first described and published by W. E. Carnegie Dickson.[2]
- In 1926, oligodendrogliomas were first classified and graded in a system devised by Bailey and Cushing, and later revised by Kernohan, Ringertz, and others, and since then, classification and grading of gliomas have evolved over the time.
- In 1979, modern classification of gliomas based on the World Health Organization (WHO) Classification of Central Nervous System Tumors was first published and revised four times since then.
- In 1997, a Westergaard's study showed that patients younger than 20 years had a median survival of 17.5 years.[3]
- In March 2001, 7 neuropathologists and 6 surgical pathologists experienced in brain tumor-diagnosis assessed 124 oligodendroglial tumors operated at the Mayo Clinic during the period of 1960 to 1990. In this study, the prognostic value of histological grading of oligodendroglial tumors in tumor grading was assessed, and significant association with survival was found for age, high cellularity, presence of mitoses, endothelial hypertrophy and proliferation and necrosis on univariate analysis. However, only age and presence of endothelial proliferation were found to be independently associated with survival on a multivariable analysis.[4]
- In 2009 Oxford Neurosymposium study by Kevin Smith, it was first discovered that there is a 69% correlation between NJDS gene mutation and oligodendroglial tumor initiation.[5]
- In 2009 ASCO Annual Meeting, it was suggested that PCV therapy may be superior in efficacy to the newer temozolomide therapy. This study showed that median time to progression for patients with 1p19q co-deletion is longer following PCV alone (7.6 years) than with temozolomide alone (3.3 years); median overall survival is also longer with PCV treatment versus temozolomide treatment (not reached, vs. 7.1 years).[6]
- Kevin Smith et al also discovered that irradiation of pituitary adenoma is associated with precipitation of oligodendroglioma.
- In 2016 edition of the most recent WHO classification, gliomas are classified based not only on histopathologic appearance but also on well-established molecular parameters.
References
- ↑ Hartmann C, von Deimling A (2009). "Molecular pathology of oligodendroglial tumors". Recent Results Cancer Res. 171: 25–49. doi:10.1007/978-3-540-31206-2_2. PMID 19322536.
- ↑ Dickson, WEC (1926), Proceeding of the Section of Neurology of the Royal Society Medicine: Oligodendroglioma of Floor of Third Ventricle, Brain-A journal of neurology, p. 578, retrieved 11/20/2015 Check date values in:
|accessdate=(help) - ↑ Engelhard, Herbert H; Stelea, Ana; Mundt, Arno (2003). "Oligodendroglioma and anaplastic oligodendroglioma:". Surgical Neurology. 60 (5): 443–456. doi:10.1016/S0090-3019(03)00167-8. ISSN 0090-3019.
- ↑ Giannini C, Scheithauer BW, Weaver AL, Burger PC, Kros JM, Mork S; et al. (2001). "Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading". J Neuropathol Exp Neurol. 60 (3): 248–62. PMID 11245209.
- ↑ Etiology of oligodendroglioma. Wikipedia. https://en.wikipedia.org/wiki/Oligodendroglioma
- ↑ . doi:10.1200/jco.2009.27.15s.2014. Missing or empty
|title=(help)